-
Je něco špatně v tomto záznamu ?
The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients
D. Slezák, O. Mayer, J. Bruthans, J. Seidlerová, M. Rychecká, J. Gelžinský, M. Mateřánková, P. Karnosová, P. Wohlfahrt, R. Cífková, J. Filipovský
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
Grantová podpora
Health Development Agency of the Czech Ministry of Health
project 17-29520 A
Specific Academic Research Project of Charles University
project SVV 260 393
Charles University Research Fund
PROGRES, project Q39
PubMed
30157533
DOI
10.1055/a-0684-9601
Knihovny.cz E-zdroje
- MeSH
- diabetes mellitus krev diagnóza farmakoterapie mortalita MeSH
- komorbidita MeSH
- krevní glukóza metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- nemoci koronárních tepen krev mortalita MeSH
- omezení příjmu potravy krev MeSH
- prediabetes krev mortalita MeSH
- prognóza MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: Impaired glucose metabolism represents one the most important cardiovascular risk factors, with steeply raising prevalence in overall population. We aimed to compare mortality risk of impaired fasting glycaemia (IFG) and overt diabetes mellitus (DM) in patients with coronary heart disease (CHD). STUDY DESIGN: prospective cohort study METHODS: A total of 1685 patients, 6-24 months after myocardial infarction and/or coronary revascularization at baseline, were followed in a prospective cohort study. Overt DM was defined as fasting glucose ≥ 7 mmol/L and/or use of antidiabetic treatment, while IFG as fasting glucose 5.6-6.99 mmol/L, but no antidiabetic medication. The main outcomes were total and cardiovascular mortality during 5 years of follow-up. RESULTS: During follow-up of 1826 days, 172 patients (10.2%) deceased, and of them 122 (7.2%) from a cardiovascular cause. Both exposures, overt DM (n=623, 37.0% of the whole sample) and IFG (n=436, 25.9%) were associated with an independent increase of 5-year total mortality, compared to normoglycemic subjects [fully adjusted hazard risk ratio (HRR) 1.63 (95%CI: 1.01-2.61)]; p=0.043 and 2.25 (95%CI: 1.45-3.50); p<0.0001, respectively]. In contrast, comparing both glucose disorders one with each other, no significant differences were found for total mortality [HRR 0.82 (0.53-1.28); p=0.33]. Taking 5-years cardiovascular mortality as outcome, similar pattern was observed [HRR 1.96 (95%CI: 1.06-3.63) and 3.84 (95%CI: 2.19-6.73) for overt DM and IFG, respectively, with HRR 0.63 (95%CI: 0.37-1.07) for comparison of both disorders]. CONCLUSIONS: Impaired fasting glycaemia adversely increases mortality of CHD patients in the same extent as overt DM.
Fakultni Nemocnice Plzen 2nd Dept of Internal Medicine Plzen Czech Republic
Fakultni Nemocnice Plzen Dept of Cardiology Plzen Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004709
- 003
- CZ-PrNML
- 005
- 20250325142742.0
- 007
- ta
- 008
- 220113s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1055/a-0684-9601 $2 doi
- 035 __
- $a (PubMed)30157533
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Slezák, David $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
- 245 14
- $a The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients / $c D. Slezák, O. Mayer, J. Bruthans, J. Seidlerová, M. Rychecká, J. Gelžinský, M. Mateřánková, P. Karnosová, P. Wohlfahrt, R. Cífková, J. Filipovský
- 520 9_
- $a OBJECTIVES: Impaired glucose metabolism represents one the most important cardiovascular risk factors, with steeply raising prevalence in overall population. We aimed to compare mortality risk of impaired fasting glycaemia (IFG) and overt diabetes mellitus (DM) in patients with coronary heart disease (CHD). STUDY DESIGN: prospective cohort study METHODS: A total of 1685 patients, 6-24 months after myocardial infarction and/or coronary revascularization at baseline, were followed in a prospective cohort study. Overt DM was defined as fasting glucose ≥ 7 mmol/L and/or use of antidiabetic treatment, while IFG as fasting glucose 5.6-6.99 mmol/L, but no antidiabetic medication. The main outcomes were total and cardiovascular mortality during 5 years of follow-up. RESULTS: During follow-up of 1826 days, 172 patients (10.2%) deceased, and of them 122 (7.2%) from a cardiovascular cause. Both exposures, overt DM (n=623, 37.0% of the whole sample) and IFG (n=436, 25.9%) were associated with an independent increase of 5-year total mortality, compared to normoglycemic subjects [fully adjusted hazard risk ratio (HRR) 1.63 (95%CI: 1.01-2.61)]; p=0.043 and 2.25 (95%CI: 1.45-3.50); p<0.0001, respectively]. In contrast, comparing both glucose disorders one with each other, no significant differences were found for total mortality [HRR 0.82 (0.53-1.28); p=0.33]. Taking 5-years cardiovascular mortality as outcome, similar pattern was observed [HRR 1.96 (95%CI: 1.06-3.63) and 3.84 (95%CI: 2.19-6.73) for overt DM and IFG, respectively, with HRR 0.63 (95%CI: 0.37-1.07) for comparison of both disorders]. CONCLUSIONS: Impaired fasting glycaemia adversely increases mortality of CHD patients in the same extent as overt DM.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a krevní glukóza $x metabolismus $7 D001786
- 650 _2
- $a komorbidita $7 D015897
- 650 _2
- $a nemoci koronárních tepen $x krev $x mortalita $7 D003324
- 650 _2
- $a diabetes mellitus $x krev $x diagnóza $x farmakoterapie $x mortalita $7 D003920
- 650 _2
- $a omezení příjmu potravy $x krev $7 D005215
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prediabetes $x krev $x mortalita $7 D011236
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mayer, Otto $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
- 700 1_
- $a Bruthans, Jan $u Fakultni Thomayerova nemocnice s poliklinikou, Centre for Cardiovascular Prevention , Praha, Czech Republic
- 700 1_
- $a Seidlerová, Jitka $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
- 700 1_
- $a Rychecká, Martina $u Fakultni Nemocnice Plzen, Dept. of Cardiology, Plzen, Czech Republic
- 700 1_
- $a Gelžinský, Julius $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
- 700 1_
- $a Mateřánková, Markéta $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
- 700 1_
- $a Karnosová, Petra, $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic $d 1985- $7 xx0330667
- 700 1_
- $a Wohlfahrt, Peter $u Fakultni Thomayerova nemocnice s poliklinikou, Centre for Cardiovascular Prevention , Praha, Czech Republic
- 700 1_
- $a Cífková, Renata $u Fakultni Thomayerova nemocnice s poliklinikou, Centre for Cardiovascular Prevention , Praha, Czech Republic
- 700 1_
- $a Filipovský, Jan $u Fakultni Nemocnice Plzen, 2nd Dept. of Internal Medicine, Plzen, Czech Republic
- 773 0_
- $w MED00009707 $t Experimental and clinical endocrinology & diabetes $x 1439-3646 $g Roč. 129, č. 1 (2021), s. 29-35
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30157533 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20250325142743 $b ABA008
- 999 __
- $a ok $b bmc $g 1752013 $s 1155858
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 129 $c 1 $d 29-35 $e 20180829 $i 1439-3646 $m Experimental and clinical endocrinology & diabetes $n Exp Clin Endocrinol Diabetes $x MED00009707
- GRA __
- $a Health Development Agency of the Czech Ministry of Health $p project 17-29520 A
- GRA __
- $a Specific Academic Research Project of Charles University $p project SVV 260 393
- GRA __
- $a Charles University Research Fund $p PROGRES, project Q39
- LZP __
- $a Pubmed-20220113